Last reviewed · How we verify
LNG-EC
LNG-EC, developed by Columbia University, is a marketed small molecule with a specific mechanism of action targeting a particular biological pathway. The key composition patent for LNG-EC is set to expire in 2028, which may provide a period of market exclusivity and protection against generics. However, the lack of detailed revenue data and primary trial results poses a significant risk in assessing its current market performance and potential future challenges.
At a glance
| Generic name | LNG-EC |
|---|---|
| Also known as | Levonorgestrel (LNG) emergency contraceptive (EC), Next Choice One Dose |
| Sponsor | Columbia University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Rct Assessing Pregnancy - Piroxicam for Ec With Levonorgestrel (PHASE3)
- Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kg (PHASE4)
- Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day Start (PHASE4)
- Effectiveness of Orally Dosed Emergency Contraception in Obese Women - LNG (PHASE4)
- Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC (PHASE2,PHASE3)
- Emergency Contraception as a Back up of Lactational Amenorrhea Method(LAM) (NA)
- EC PK in Women With Normal and Obese BMI (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LNG-EC CI brief — competitive landscape report
- LNG-EC updates RSS · CI watch RSS
- Columbia University portfolio CI